These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7848325)

  • 41. Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.
    Osuga T; Ikura Y; Kadota C; Hirano S; Iwai Y; Hayakumo T
    Int J Clin Exp Pathol; 2015; 8(2):1961-6. PubMed ID: 25973089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines.
    Tugwell P; Bennett K; Bell M; Gent M
    Ann Intern Med; 1989 Apr; 110(8):581-3. PubMed ID: 2648921
    [No Abstract]   [Full Text] [Related]  

  • 43. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.
    Berthelot JM; Maugars Y; Prost A
    Arthritis Rheum; 1997 Jan; 40(1):193-4; author reply 195-6. PubMed ID: 9008619
    [No Abstract]   [Full Text] [Related]  

  • 44. Incidence of pancytopenia with methotrexate treatment of rheumatoid arthritis in Germany: comment on the article by Gutierrez-Ureña et al.
    Kassai A; Rautenstrauch H
    Arthritis Rheum; 1997 Jan; 40(1):195-6. PubMed ID: 9008621
    [No Abstract]   [Full Text] [Related]  

  • 45. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
    Lertnawapan R; Chonprasertsuk S; Siramolpiwat S
    Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methotrexate: adverse reactions and major toxicities.
    Goodman TA; Polisson RP
    Rheum Dis Clin North Am; 1994 May; 20(2):513-28. PubMed ID: 8016424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.
    Dávila-Fajardo CL; Swen JJ; Cabeza Barrera J; Guchelaar HJ
    Pharmacogenomics; 2013 Jan; 14(1):63-73. PubMed ID: 23252949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methotrexate Hepatotoxicity Monitoring Guidelines in Psoriasis and Rheumatoid Arthritis: Is There a Consensus?
    Clary DD; Reid AT; Kiani R; Fanciullo J
    S D Med; 2021 Aug; 74(8):363-366. PubMed ID: 34461001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Methotrexate].
    Rau R
    Z Rheumatol; 2016 Aug; 75(6):599-603. PubMed ID: 27365027
    [No Abstract]   [Full Text] [Related]  

  • 50. Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record.
    Lin C; Karlson EW; Dligach D; Ramirez MP; Miller TA; Mo H; Braggs NS; Cagan A; Gainer V; Denny JC; Savova GK
    J Am Med Inform Assoc; 2015 Apr; 22(e1):e151-61. PubMed ID: 25344930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis.
    Shergy WJ; Polisson RP; Caldwell DS; Rice JR; Pisetsky DS; Allen NB
    Am J Med; 1988 Dec; 85(6):771-4. PubMed ID: 3195601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serious adverse events-missing in action: comment on the article by Kremer et al.
    Leonardi CL
    Arthritis Rheum; 2012 Sep; 64(9):3055-6; author reply 3056-7. PubMed ID: 22674338
    [No Abstract]   [Full Text] [Related]  

  • 53. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.
    Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S
    Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methotrexate in rheumatoid arthritis.
    Furst DE; Kremer JM
    Arthritis Rheum; 1988 Mar; 31(3):305-14. PubMed ID: 2965875
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature.
    Visser K; van der Heijde DM
    Clin Exp Rheumatol; 2009; 27(6):1017-25. PubMed ID: 20149325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.
    Nygaard H
    Arthritis Rheum; 1997 Jan; 40(1):194-5; author reply 195-6. PubMed ID: 9008620
    [No Abstract]   [Full Text] [Related]  

  • 57. Low-dose methotrexate therapy and hepatotoxicity. The view of the hepatologist.
    Watson RG; Smallwood RA
    Med J Aust; 1991 Oct; 155(7):428-30. PubMed ID: 1921807
    [No Abstract]   [Full Text] [Related]  

  • 58. [Liver diseases in rheumatoid and psoriatic arthritis].
    Santiago García D; Saturansky E; Poncino D; Ortiz V; Martínez Artola Y; Rosenberg S; Abritta G; Palermo C; Enriquez N; Cravero A
    Acta Gastroenterol Latinoam; 2012 Jun; 42(2):112-9. PubMed ID: 22876713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate-induced liver abnormalities in rheumatoid arthritis.
    Bridges SL; Alarcón GS; Koopman WJ
    J Rheumatol; 1989 Sep; 16(9):1180-3. PubMed ID: 2681761
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.
    Prey S; Paul C
    Br J Dermatol; 2009 Mar; 160(3):622-8. PubMed ID: 18945303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.